Trial Details
TERMINATEDBasic Information
| Clinical ID | c2268 |
|---|---|
| Identifier | NCT03759288 |
| Trial Title | An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn's Disease|IBD |
| Interventions | DRUG: Brazikumab low dose|DRUG: Brazikumab high dose|DRUG: Humira®|DRUG: Placebo |
Participant Information
| Sponsor | AstraZeneca |
|---|---|
| City | Phoenix |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2|PHASE3 |
Time Information
| Start Date | 2018-12-07 |
|---|---|
| Primary Completion Date | 2023-10-18 |
| Completion Date | 2023-10-18 |